Senior Leadership

Jason Attanucci

Smart Imaging Strategy to Accelerate Drug Development
Jason

Jason Attanucci

Chief Commercial Officer
Biotech and Pharma Drug Development
He is responsible for leading IAG's commercial strategy, with a focus on strengthening client relationships, driving revenue growth, and expanding the company's global market presence. Attanucci brings nearly 30 years of proven leadership experience in the life sciences and technology industries to IAG. His appointment is seen as a strategic move to drive growth and deliver innovative imaging and AI-driven insights to IAG's clients.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Dr. Olga Kubassova

Smart Imaging Strategy to Accelerate Drug Development
5c77eb91-3d58-4580-be24-929bb4b7f2a0

Dr. Olga Kubassova

Founder and President
Extensive expertise in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics.
Dr. Olga Kubassova is the founder and current President of Image Analysis Group (IAG), a position she has held since 2024 after serving as the company's CEO for over 15 years. She founded IAG shortly after completing her PhD, with the goal of commercializing her research and bringing innovative imaging solutions to clinical trials. Dr. Kubassova's background is in mathematics and computer science, with degrees from St. Petersburg State University, Lappeenranta University of Technology, and a PhD from the University of Leeds6. Her expertise lies in identifying innovative approaches to clinical research, disruptive technology platforms, and novel therapeutics. Under her leadership, IAG has grown into a global player in clinical development, providing advanced medical imaging and artificial intelligence solutions for drug development. The company has partnerships with top pharmaceutical companies, innovative biotech and medtech players, and maintains its own portfolio companies. Dr. Kubassova is also known for her commitment to supporting women in leadership positions, being a founding member of 'The 2% club'. Her vision for IAG continues to focus on leveraging technology and AI to optimize clinical trials and accelerate drug development.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Christophe Berthoux, MD

Smart Imaging Strategy to Accelerate Drug Development
archimed-christophe-2_3

Christophe Berthoux, MD

Chairman
Biotech and Pharma Drug Development Strategy
Christophe Berthoux has been serving as the Chairman of Image Analysis Group (IAG) since September 1, 2018, bringing over 20 years of leadership experience in the clinical research industry. Prior to IAG, he held key positions including CEO of Synexus Limited, Chief Executive of Citoxlab, and Chief Commercial Officer at Charles River Laboratories International Inc. Dr. Berthoux, who holds a doctorate in veterinary medicine and an MBA from Purdue University, was appointed to develop IAG's growth and people strategies, leveraging his extensive expertise in international clinical trials. His leadership at IAG focuses on driving successful growth and international expansion for the company, while he also serves as an Operating Partner at ArchiMed and CEO of NAMSA.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Jon Himoff

Smart Imaging Strategy to Accelerate Drug Development
Himoff

Jon Himoff

Chief Product Officer
Leading Product Design and Engineering organization with P&L ownership and customer focus.
Turning concepts into new tech-driven businesses and growing them rapidly, is what I enjoy working on the most. I went from blank sheets of paper to an idea, to team creation, to early stage funding, to a multi-million $ sale to a US public company. I have also worked with companies that have great assets, but have lacked a fresh, energetic approach which focuses on next generation offerings and reaches more prospective customers faster.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Richard Barker, OBE

Smart Imaging Strategy to Accelerate Drug Development
Richard_Barker-135x206

Richard Barker, OBE

Board Member and Recognized Global Expert in Pharmaceutical Industry
Professor Richard Barker, OBE, is a visionary leader in healthcare and life sciences, dedicated to accelerating the development and adoption of precision medicine globally. As the Founding Director of New Medicine Partners and Chair of Metadvice, he spearheads initiatives that leverage cutting-edge technologies to revolutionize patient care. His expertise spans precision medicine, AI-driven medical decision-making, healthy longevity, and the integration of therapeutics, diagnostics, and medical informatics. With a distinguished career that includes roles as the Director General of the Association of the British Pharmaceutical Industry and leadership positions at IBM Healthcare Solutions and Chiron Diagnostics, Prof. Barker brings unparalleled experience to his current endeavors. He has been instrumental in founding the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI) and continues to shape healthcare policy and innovation as the Chairman of the South London Health Innovation Network. Recognized for his contributions with an OBE in 2012, Prof. Barker remains at the forefront of healthcare transformation. As a Visiting Professor at King's College London and author of influential books on the future of healthcare, he continues to inspire and guide the next generation of healthcare innovators. His work focuses on reimagining R&D and regulatory processes to bring advanced treatments to patients more rapidly and affordably, embodying his commitment to improving global health outcomes through innovation and collaboration.
RETURN TO ALL EXPERTS >
IAG (Image Analysis Group)

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Michael Clark, PMP

Smart Imaging Strategy to Accelerate Drug Development
MichaelClark

Michael Clark, PMP

Chief Operating Officer
Bone Health Expert
Michael Clark is the Chief Operating Officer (COO) at Image Analysis Group (IAG), a leading provider of image analysis solutions for the biotechnology and pharmaceutical industries. He has been in this role since January 2019, based in London, United Kingdom. Mr. Clark brings extensive experience in clinical project management and operations to his role at IAG. He has a background in managing global clinical programs and implementing project management offices (PMOs) in previous positions. Michael Clark's expertise in clinical trials and medical imaging is relevant to bone health research. He has been involved in discussions around the use of imaging techniques like DXA (Dual-Energy X-ray Absorptiometry) analysis, which is a key tool for measuring bone mineral density and body composition. At IAG, Clark works alongside other experts who specialize in musculoskeletal imaging and the development of novel therapeutics for rheumatic and autoimmune conditions. This collaboration likely enhances IAG's capabilities in bone health-related imaging and research. Clark's role at IAG involves building teams and scaling capabilities to deliver global-scale imaging clinical trials, which may include studies related to bone health and osteoporosis. His expertise in clinical operations and imaging technology positions him as a key figure in advancing medical imaging applications, including those relevant to bone health research and drug development.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Prof. Mikael Boesen MD, PHD

Smart Imaging Strategy to Accelerate Drug Development
Mikael

Prof. Mikael Boesen MD, PHD

Therapeutic Area Lead for Rheumatic Diseases and Autoimmunity
NED, Rheumatic Diseases and Autoimmunity
Prof. Mikael Boesen, MD, PhD, is a renowned radiologist specializing in musculoskeletal imaging and the development of novel therapeutics for rheumatic and autoimmune conditions. He serves as the Therapeutic Area Lead for Rheumatic Diseases and Auto-Immunity at Image Analysis Group (IAG), where he plays a pivotal role in advancing imaging strategies for clinical trials. Prof. Boesen is also the head of musculoskeletal imaging and research groups at Copenhagen University and Bispebjerg and Frederiksberg Hospital in Denmark. With over 20 years of international experience in clinical research on inflammatory and degenerative joint diseases, he has served as a global principal investigator and expert reader on numerous trials. His work bridges multiple therapeutic areas, including immuno-oncology and cardiac imaging, and he actively spearheads the integration of artificial intelligence into radiological image analysis across Europe and the United States. As an author of more than 200 articles, chapters, and abstracts, Prof. Boesen has also supervised over 30 PhD students and postdoctoral researchers. At IAG, he leverages his expertise to guide drug development companies in designing innovative clinical trials and selecting optimal imaging strategies, ensuring precision and efficiency in evaluating novel treatments.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Prof. Sotirios Bisdas, MD, PhD

Smart Imaging Strategy to Accelerate Drug Development
prof_4797_20240215130640

Prof. Sotirios Bisdas, MD, PhD

Therapeutic Area Lead for Neuroimaging, Neuro-Oncology, Advanced Oncology
Neuroimaging, Neuro-Oncology, Advanced Oncology
Prof. Bisdas is IAG’s Therapeutic Area Lead for Neuroimaging, Neuro-Oncology and Advanced Oncology. He is a Board certified neuro-oncologists, lead the Department of Neuroradiology at the National Hospital of Neurology and Neurosurgery in London, Associate Professor of Neuroradiology at University College London, Professor of Radiology at Eberhard Karls University Tübingen, Germany, Honorary Consultant Neuroradiologist at the Great Ormond Street Hospital for Children, and Neurooncology Imaging Research Lead. His fields of expertise include functional CT and MR imaging, and molecular MR-PET in brain, spine and head and neck diseases. He has authored or co-authored more than 150 peer-reviewed publications and 10 book chapters. Prof. Bisdas has been actively involved in MR-PET imaging, since its launch in 2009, as well as in intraoperative MR imaging and ultra-high-field brain MR spectroscopy. He is member of the editorial board of European Radiology, Insights into Imaging, BioMed Research, and Radiology Research and Practice. He is also editor-in-chief for the Head and Neck section of the European Journal of Radiology. He is actively engaged in professional societies being a member of the Executive Committee of the European Society of Head and Neck Radiology, member of the Executive Committee of the European Society of Medical Imaging and Informatics, member of the European Society of Radiology Research Committee, and member of the Head and Neck and IT Committees of the European Society of Neuroradiology.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events

Dr. Jan Lundberg, MD, PhD

Smart Imaging Strategy to Accelerate Drug Development
Jan Lundberg_TB Alliance Board of Directors

Dr. Jan Lundberg, MD, PhD

Chair of IAG's Client Advisory Board and Scientific Advisory Board
Novel Drug Discovery and Development
Dr. Jan Lundberg, MD, PhD joined Image Analysis Group (IAG) in 2018 as Chair of the Scientific Advisory Board and also serves as a Non-Executive Director on IAG's corporate board. With over 22 years of experience in global pharmaceutical R&D, Dr. Lundberg brings invaluable expertise to IAG's scientific strategy and partnerships. In his role at IAG, Dr. Lundberg leads the distinguished board of in-house scientists, imaging experts, and academic collaborators. He works closely with biotech and pharma partners, leveraging his extensive experience in drug discovery and development to provide critical assessments of novel therapeutic agents and strategic positioning to maximize their chances of success. Dr. Lundberg's contributions to IAG's strategy include: Guiding IAG's scientific vision as a powerhouse in the industry Driving partnerships with major pharmaceutical companies Supporting IAG's global expansion efforts Advising on the use of advanced imaging technologies across therapeutic areas His expertise in imaging, particularly in areas like amyloid and tau PET imaging for Alzheimer's research, aligns well with IAG's focus on leveraging technology and AI to optimize clinical trials and accelerate drug development. Dr. Lundberg's involvement enhances IAG's ability to provide early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations. This supports IAG's mission to de-risk clinical development and deliver lifesaving therapies to patients more quickly. By bringing his vast experience from leadership roles at Eli Lilly, AstraZeneca, and his academic background at Karolinska Institutet, Dr. Lundberg strengthens IAG's position as a unique partner to life sciences companies, helping them navigate the complex landscape of clinical trials and strategic planning in drug development.
IAG, Image Analysis Group

Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.

Image Management Platform

Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.

Contact Us
Careers

In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.

Events